Medco 2015 Annual Report Download - page 23

Download and view the complete annual report

Please find page 23 of the 2015 Medco annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 100

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100

21 Express Scripts 2015 Annual Report
Forward-Looking Statements and Associated Risks
Information we have included or incorporated by reference in this Annual Report on Form 10-K, and information
which may be contained in our other filings with the Securities and Exchange Commission (“the SEC”) and our press releases
or other public statements, contains or may contain forward-looking statements. These forward-looking statements include,
among other things, statements of our plans, objectives, expectations (financial or otherwise) or intentions.
Our forward-looking statements involve risks and uncertainties. Our actual results may differ significantly from those
projected or suggested in any forward-looking statements. We do not undertake any obligation to release publicly any revisions
to such forward-looking statements to reflect events or circumstances occurring after the date hereof or to reflect the
occurrence of unanticipated events. Any number of factors could cause our actual results to differ materially from those
contemplated by any forward-looking statements, including, but not limited to, the risks associated with the following:
STANDARD OPERATING FACTORS
• our ability to remain profitable in a very competitive marketplace depends upon our continued ability to attract
and retain clients while maintaining our margins, differentiate our products and services from those of our
competitors, and develop and cross-sell new products and services to our existing clients
• our failure to anticipate and appropriately adapt to changes or trends within the rapidly changing healthcare
industry
• changes in applicable laws, rules or regulations, or their interpretation or enforcement, or the enactment of new
laws, rules or regulations, which apply to our business practices (past, present or future) or require us to spend
significant resources for compliance
• a failure in the security or stability of our technology infrastructure, or the infrastructure of one or more of our
key vendors
• our failure to execute on, or other issues arising under, certain key client contracts
• significant changes within the pharmacy provider marketplace, including the loss of or adverse change in our
relationship with one or more key pharmacy providers
• changes to the healthcare industry designed to manage healthcare costs or alter healthcare financing practices or
changes to government policies in general
• a significant failure or disruption in service within our operations or the operations of our vendors
• changes relating to Medicare Part D, our failure to comply with CMS regulatory requirements, our failure to
comply with CMS contractual requirements applicable to us as a Medicare Part D PDP sponsor or our failure to
otherwise execute on our strategies related to Medicare Part D
• our failure to effectively execute on strategic transactions or successfully integrate the business operations or
achieve the anticipated benefits from any acquired businesses
• a failure to adequately protect confidential health information received and used in our business operations
• the termination, loss, or an unfavorable modification, of our relationship with one or more key pharmaceutical
manufacturers, or the significant reduction in payments made or discounts provided by pharmaceutical
manufacturers
• results in pending and future litigation, investigations or other proceedings which could subject us to significant
monetary damages or penalties and/or require us to change our business practices, or the costs incurred in
connection with such proceedings
• our failure to attract and retain talented employees, or to manage succession and retention for our Chief
Executive Officer or other key executives
• changes in drug pricing or industry pricing benchmarks
• the impact of our debt service obligations on the availability of funds for other business purposes, the terms of
and our required compliance with covenants relating to our indebtedness and our access to the credit markets in
general
• the delay, reduction, suspension or cancellation of government spending or appropriations relating to our
business